Biotargeting
Νέα
 | E-mail: |
Dr Haralabos Kalofonos is a Professor of Medical Oncology, Director of the Division of Oncology and Clinical Oncology Laboratory at the University of Patras, Greece. His work is multi-dimensional and includes clinical practice and basic science. Dr. Kalofonos participates in the design of clinical trials (phase II and III) organized by Cooperative Groups as well as in international multi-centered clinical trials phase II, III and IV, to evaluate the therapeutic efficacy of new anticancer agents and/or their combination with chemotherapy.
Furthermore, Dr. Kalofonos conducts research on patients’ quality of life during and after chemotherapy or targeted therapy in order to improve treatment’s serious adverse events such as pain, anemia, depression, etc. His continuing interest on the role the psychosocial factors have in patients’ total function has led to the development of Quality of Life and Supportive Care Multidisciplinary Group.
Regarding basic research, Dr. Kalofonos has considerable experience in the development and applications of monoclonal antibodies for cancer treatment. Furthermore, his scientific interest is also focused on research for markers with prognostic and predictive role in cancer using molecular oncology techniques. Clinical Oncology Laboratory has developed a bank of fresh frozen human tissues including colon cancer and non small cell lung cancer.
Clinical practice as well as basic research will contribute to understanding carcinogenesis and tumor development for cancer management improvement. Dr. Kalofonos collaborates with several Departments of the University of Patras as also with Universities, Hospitals and Institutes in Greece and abroad (Medical Research Council – Hammersmith Hospital, UK, Institute Tumori Milan, Stony Brook University, USA, etc.).